CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013
OPERATING ACTIVITIES:
Net income (loss)	$ 16,838		$ (34,838)	[1]
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	45,105		35,695	[1]
Non-cash impairment charges	600		46,738	[1]
Deferred income tax (benefit)	(1,510)		(7,238)	[1]
Amortization of debt issuance costs	2,060		1,707	[1]
Non-cash interest expense	5,256		4,865	[1]
Loss on disposal of property and equipment	505		1,816	[1]
Loss/(gain) from increase/(decrease) in fair value of contingent consideration liabilities	(878)		0	[1]
Share-based compensation	11,688		7,594	[1]
Excess tax benefits from stock-based compensation arrangements	(1,207)		(140)	[1]
Changes in assets and liabilities, net of business acquisitions:
Accounts receivable	(3,847)		1,440	[1]
Inventories	(26,648)		(28,765)	[1]
Prepaid expenses and other current assets	6,628		(694)	[1]
Other non-current assets	(437)		(515)	[1]
Accounts payable, accrued expenses and other current liabilities	8,794		14,185	[1]
Deferred revenue	1,069		986	[1]
Other non-current liabilities	(5,310)		(1,264)	[1]
Net cash provided by operating activities	58,706		41,572	[1]
INVESTING ACTIVITIES:
Purchases of property and equipment	(29,466)		(37,722)	[1]
Sales of property and equipment	0		533	[1]
Cash used for business acquisition, net of cash acquired	(235,000)		(2,980)	[1]
Net cash used in investing activities	(264,466)		(40,169)	[1]
FINANCING ACTIVITIES:
Borrowings under senior credit facility	385,000		30,000	[1]
Repayments of Secured Debt	160,000		10,000
Payments of Debt Issuance Costs	(3,110)		(1,053)	[1]
Principal payments under capital lease obligations	(370)		0	[1]
Proceeds from exercised stock options	8,317		420	[1]
Excess tax benefits from stock-based compensation arrangements	1,207		140	[1]
Net cash provided by financing activities	231,044		19,507	[1]
Effect of exchange rate changes on cash and cash equivalents	(5,667)		1,020	[1]
Net change in cash and cash equivalents	19,617		21,930	[1]
Cash and cash equivalents at beginning of period	120,614	[1]	96,938	[1]
Cash and cash equivalents at end of period	$ 140,231		$ 118,868	[1]

[1] See Note 1 of these condensed consolidated financial statements for discussion of the impact of the change in accounting for the medical device excise tax.